Bitterroot Bio’s Post

More than 3,900 patients have been treated in clinical studies with Pantera Lux drug-coated balloon (DCB), investigating coronary DCBs for various indications. Listen to Hee Hwa Ho, who summarizes the benefits of coronary DCBs beyond ISR. Find out more about Pantera Lux and its clinical data 👉 https://ow.ly/8YxY50PY1rf #BIOTRONIK #PanteraLux #WhatWouldYouChoose

Discover a clinically proven solution for #ThyroidRFA that’s minimally invasive, FDA-cleared, and has been performed on over 100,000 patients worldwide. Learn more about the #STARmed RF System and why it’s been used in over 70% of peer-reviewed thyroid RFA clinical studies(1): https://bit.ly/4dFvaqs (1): Data on File Product Indications: The VIVA combo RF System is FDA-cleared. It is intended for use in percutaneous and intraoperative coagulation and ablation of tissue.

News of the week: 12-month results for Phase 2 trial evaluating heat-therapy system for MGD, topline results from targeted photobiomodulation for treatment of progressive myopia, enrollment complete in Phase 3 trials to evaluate new wet AMD therapy, and more. Read all about it in EyeWorld Weekly

Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg http://ow.ly/XzxC105z0m8

🔬 Innovative Breakthrough in Lupus Treatment 🔬 🚫 No Lymphodepletion Required: One of the most notable aspects of this therapy is that it can be administered without the use of lymphodepletion, reducing the burden on patients, physicians, and the healthcare system. This is especially important considering the significant comorbidities associated with SLE. Exciting news from Synthekine! Their unique combination therapy, SYNCAR-001 + STK-009, has been cleared by the FDA for a clinical trial in the US to tackle systemic lupus erythematosus (SLE) and lupus nephritis (LN) without the need for lymphodepletion. This marks a significant step forward in the treatment of these challenging autoimmune diseases. 🎯 The Power of Combination Therapy: The therapy combines an autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) product with an engineered pegylated IL-2 cytokine. This innovative approach aims to drive cell engraftment and controlled cell expansion, offering a potential game-changer for patients with nonrenal SLE and LN. 🌍 Global Potential: As this therapy moves into clinical trials, it holds the promise of addressing critical segments of the patient population who face barriers to treatment. With preclinical results showing control of cell expansion and activation, there's a remarkable potential benefit for those suffering from this devastating disease. 💡 Insight: This breakthrough demonstrates the power of innovative therapies in addressing key limitations of current treatments. As we continue to explore the potential of CAR-T cell therapies, it's exciting to see advancements like these that could significantly improve the lives of patients around the world. #LupusTreatment #Synthekine #CAR-TTherapy #InnovativeTherapies #AutoimmuneDiseases #ClinicalTrials #HealthcareInnovation

The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year¹: https://bit.ly/4eb8a31 Risk Info: https://bit.ly/4aKlCI1 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

📌First-line choice for DVT treatment is: ✅️ Low molecular weight heparins (LMWHs) given S/C and DOACs ... ▪️LMWHs and DOACs are first-line treatment options for patients with cancer-associated DVT , this including patients who have a central venous catheter and develop DVT. ▪️Warfarin is a 2nd-line alternative due to its low cost, but use requires careful monitoring. 📌 NB. : DOACs = Direct Oral Anticoagulants... Ex: Rivaroxaban . Dabigatran . Apixaban . Edoxabsn . #Drug_Awareness

The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/4aryVhk Risk Info: https://bit.ly/49AjEJz TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

Dr. Shin and his group recently published a retrospective, single-center study comparing therapeutic efficacy and technical outcomes between conventional fixed electrodes and adjustable electrodes in the RFA of benign thyroid nodules. After evaluating 182 nodules on 173 patients, they concluded that adjustable electrodes demonstrated better technical outcomes than fixed electrodes in terms of RFA time, ablated volume/energy, and ablated volume/time. Read: https://lnkd.in/esetzat8  Learn more about STARmed technologies: STARmed-America.com #STARmedRFA #ThyroidNoduleTreatment

The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year:¹ https://bit.ly/49SGIU1 Risk Info: https://bit.ly/3UtKYF2 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.